Erika G. Puente

Anesthesia in the Intraoperative MRI Environment

Intraoperative MRI (iMRI) can be applied in several surgical settings. The incorporation of MRI technology into the operating room requires special considerations. The size and design of the operating room, including the equipment introduced into this setting, must be MR safe and allow adequate anesthesia monitoring and care. There are general restrictions and perils that may present in an operating room setting because of the MRI technology involving the monitoring equipment, anesthesia machine, and infusion devices. Incorporating the MRI technology into the operating room presents a new challenge in a transdisciplinary environment. The use of the iMRI technology has provided revolutionary tools for the new generation of medical practice.

Postoperative nausea and vomiting prophylaxis from an economic point of view.

Patients rank postoperative nausea and vomiting (PONV) in the top five most undesirable outcomes of surgery. Thirty percent of all surgical patients experience PONV. We conducted an economic study to determine the financial implications of providing surgical patients with PONV prophylaxis to increase patient satisfaction and minimize postoperative complications. Our main objective was to develop an economic model of PONV prophylaxis. We retrospectively reviewed all surgical cases who received care at our institution from June 2005 to June 2007 in which the surgical patient was billed for treatment of nausea and vomiting while in the hospital. The PONV risk factors for these patients were assessed as well as the revenue stream associated with those patients who returned to the hospital within 5 days with nausea and vomiting as their chief complaint. Of the total number of medical charts reviewed (56,532), 28 (1.57%) of 1783 patients who were billed for PONV while in the hospital returned to the hospital with PONV. The total billable charges for PONV for these returning patients were

Intraoperative MRI (ioMRI) in the Setting of Awake Craniotomies for Supratentorial Glioma Resection

83,674; the total reimbursements were

Clevidipine butyrate: a promising new drug for the management of acute hypertension

25,816 yielding a 31% reimbursement rate. The total hospital expenses were

A Prospective, Comparative Study for the Evaluation of Postoperative Pain and Quality of Recovery in Patients Undergoing Robotic Versus Open Hysterectomy for Staging of Endometrial Cancer.

24,123 yielding a net hospital profit of

In vitro assessment of clevidipine using the profilin1 hypertensive mouse model.

1693 for treating these 28 patients. The average hospital cost and charge per antiemetic drug dose was

Studying the Effectiveness of Triple Therapy with Palonosetron,Dexamethasone and Promethazine for Prevention of Post OperativeNausea and Vomiting in High Risk Patients Undergoing NeurologicalSurgery and General Anesthesia

0.304 and

Studying the Effectiveness of Triple Therapy with Scopolamine, Ondansetron and Dexamethasone for Prevention of Post Operative Nausea and Vomiting in High Risk Patients Undergoing Neurological Surgery and General Anesthesia

3.66, respectively. Using these figures, we determined that our hospitals net profit increases linearly with increased PONV prophylaxis administration. Our economic analysis shows that PONV prophylaxis is economically beneficial for the hospital when weighed against the expenses generated by treating patients returning to the hospital with PONV.

BMI as a predictor for potential difficult tracheal intubation in males

Both awake craniotomy under conscious sedation and use of intraoperative MRI can increase the efficiency and safety of glioma resections. In contrast to craniotomies under general anesthesia, neurosurgery under conscious sedation requires several changes to the routine operative setup when performed in the ioMRI environment. This work reports our experience with awake craniotomies under conscious sedation using ioMRI. Seven patients underwent awake-craniotomies for resection of supratentorial gliomas using ioMRI at the Ohio State University Medical Center and James Cancer Hospital by a single surgeon. ioMRI can be safely employed in patients who are undergoing craniotomies under conscious sedation. Particularly important is the evaluation by the anesthesiologist whether the patient is a good candidate to sustain a likely longer than average procedure in a setting where his active cooperation is not only required, but also the essential aspect of this procedure.

A Prospective, Multicenter, Single-Blind Study Assessing Indices of SNAP II Versus BIS VISTA on Surgical Patients Undergoing General Anesthesia

Clevidipine butyrate is an ultrashort-acting intravenous dihydropyridine calcium-channel blocker that has been approved by the FDA for the reduction of blood pressure when oral therapy is not feasible. Hypertension is a global disease that affects more than 1 billion people worldwide and 75 million people in the USA. There are multiple agents available for the management of hypertension. The acute setting is where the challenge arises for developing new agents that not only decrease, but more importantly, optimally control blood pressure. Many drugs lower blood pressure; however, only a few have the capacity to precisely control hypertension in the acute phase. Clevidipine has unique pharmacodynamic and pharmacokinetic properties that enable the fast, safe and adequate reduction of blood pressure in hypertensive emergencies, with unique precision necessary to maintain the target blood pressure range. Its use in different clinical settings has been evaluated in several Phase I, II and III clinical studies. It is easily administered and titrated with minimal side effects, achieves fast control with low doses, is highly successful as monotherapy and allows excellent transition to oral medication. Thus, clevidipine is a promising new agent for the management of acute hypertension in a variety of clinical settings.